PARP1 and neoplasm: Recent studies suggested KP372-1 as a promising and potent NQO1-dependent anti-tumor agent that induced dramatic ROS generation and DNA damage, leading to PARP1 hyperactivation and a decrease in NAD+/NADH redox state, which suppressed tumor cell growth in vitro and in vivo (26, 27).